Inferior Outcomes after Late use of Direct-Acting Antiviral Agents in Patients with Recurrent Hepatitis C Infection after Liver Transplantation

1. Abstract
1.1. Background
Recurrent hepatitis C virus (HCV) infection after liver transplantation results in subsequent accelerated fibrosis. However, the prognosis as it relates to the timing of direct-acting antiviral (DAA) treatment after liver transplantation has not been widely investigated.